Many bluebird bio, Inc.(BLUE) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. bluebird bio Inc was Downgraded by ROTH Capital to Neutral on Feb 6, 2017. Company shares were Reiterated by Maxim Group on Dec 1, 2016 to Buy, Raises Price Target to $ 87 from a previous price target of $57 .
Company has reported several Insider transactions to the SEC, on Feb 3, 2017, David Davidson (Chief Medical Officer) sold 2,000 shares at 74.03 per share price.On Feb 2, 2017, James Mandell (director) sold 8,000 shares at 75.04 per share price.On Jan 31, 2017, Daniel Lynch (director) sold 1,000 shares at 70.09 per share price.
bluebird bio Inc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $-2.07 EPS for the quarter, missing the analyst consensus estimate by $ -0.48. Analyst had a consensus of $-1.59. The company had revenue of $1.55 million for the quarter, compared to analysts expectations of $1.82 million. The companys revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.18 EPS.
bluebird bio, Inc. (NASDAQ:BLUE) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.71 by 14 Brokerage Firm. 10 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell.
bluebird bio, Inc. (NASDAQ:BLUE) shares are expected to touch $82.08 in the short term. This short term price target has been shared by 12 analysts. However, the standard deviation of short term price estimate has been valued at 20.48. The target price could hit $120 on the higher end and $37 on the lower end.
bluebird bio, Inc. (NASDAQ:BLUE) rose 3.73% or 2.85 points on Tuesday and made its way into the gainers of the day. After trading began at $76.15 the stock was seen hitting $80.2 as a peak level and $75.8 as the lowest level. The stock ended up at $79.3. The daily volume was measured at 821,880 shares. The 52-week high of the share price is $80.2 and the 52-week low is $35.37. The company has a market cap of $2,958 million.
Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.